With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

O’Reilly Auto Parts will become the title sponsor for NASCAR’s second-tier national series when the Xfinity Series is renamed ...

Architect Levitt Bernstein, in collaboration with low energy specialist Etude, has developed a three-part document package for Greater Manchester Combined Authority, to help applicants comply with the ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Pfizer (NYSE: PFE) reported that its Phase III THRIVE-131 study of inclacumab, an experimental P-selectin inhibitor for ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer Inc. (NYSE:PFE) is not included in our list of the 30 most popular stocks among hedge funds. According to our data, 99 hedge fund portfolios held positions in Pfizer Inc. (NYSE:PFE) at the ...